NDA 020975 · Liebel-Flarsheim
Optimark
Gadoversetamide · Injection
DiscontinuedLast checked: Nov 20, 2026Latest source record: Nov 2, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Dec 8, 1999
Approved uses
3
Original approval plus efficacy supplements
Registered trials
3
0 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 4, 2006 Supplement 9 · Efficacy LabelLetter
- Jan 31, 2003 Supplement 3 · Efficacy ReviewLabelLetter
- Dec 8, 1999 Original approval · Type 3 - New Dosage Form Other Important Information from FDAReviewLetter
1 products under this application
- OPTIMARK · GADOVERSETAMIDE 16.545GM/50ML (330.9MG/ML) · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Gadoversetamide" as an intervention, any sponsor and status, largest first.
- Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00862459 · 237 participants · Start Aug 2005 · Primary completion Mar 2007
Drug: Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875); Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875) and 2 more · For: Brain Diseases; Spinal Cord Diseases
Sites: Sacramento, California; San Diego, California; Jacksonville, Florida · 27 sites in all
GuerbetIndustry
NCT01092754 · 100 participants · Start May 2002 · Primary completion Dec 2003
Drug: Gadoversetamide · For: Pathological Processes
Sites: Little Rock, Arkansas; San Diego, California; Miami, Florida · 12 sites in all
Daniel S. BermanAcademic, hospital or other
NCT01949844 · 44 participants · Start May 16, 2014 · Primary completion Jan 15, 2017
Drug: regadenoson; Optimark® · For: Coronary Artery Disease; CAD
Sites: Los Angeles, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety assessment of gadoversetamide (OptiMARK) administered by power injector.
Abdou N, Napoli AM, Hynes MR, et al. · J Magn Reson Imaging 2004 · Clinical Trial, Randomized Controlled Trial
- A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: results of a Phase III clinical trial.
Rubin DL, Desser TS, Semelka R, et al. · J Magn Reson Imaging 1999 · Clinical Trial, Clinical Trial, Phase III
- Safety of gadoversetamide in patients with acute and chronic myocardial infarction.
Huber S, Muthupillai R, Cheong B, et al. · J Magn Reson Imaging 2008 · Clinical Trial, Phase II, Multicenter Study
- The OptiMARK clinical development program: summary of safety data.
Brown JJ, Kristy RM, Stevens GR, et al. · J Magn Reson Imaging 2002 · Clinical Trial, Clinical Trial, Phase I
- Measurement of serum calcium concentration after administration of four gadolinium-based contrast agents to human volunteers.
Brown JJ, Hynes MR, Wible JH · AJR Am J Roentgenol 2007 · Clinical Trial, Research Support, Non-U.S. Gov't
- The safety and efficacy of neuroimaging with gadoversetamide injection in pediatric patients.
Lowe LH, Kearns GL, Wible JH · Curr Med Res Opin 2006 · Clinical Trial, Multicenter Study
Sponsor: Liebel-Flarsheim
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.